Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in  Metastatic Colorectal Cancer: Synergy or Antagonism?

<table>Median overall survival in PACCE and CAIRO2.  Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; Iri: irinotecan; Ox: oxaliplatin; Pmab: panitumumab.</table>

Journal of Oncology

fig1

Figure 1

Figure 1: Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in  Metastatic Colorectal Cancer: Synergy or Antagonism? 

Figure 1 | Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in  Metastatic Colorectal Cancer: Synergy or Antagonism? 